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CORRESPONDENCE
Is Aspirin Still the Antiplatelet Drug of Choice
for Patients with Peripheral Arterial Disease?
Sir,
The comprehensive review by Burns et al. considers
the best medical treatment for peripheral arterial
disease (PAD).1 The antiplatelet therapy section states
that aspirin is the first-line antiplatelet drug of
choice. However, there is evidence of aspirin resist-
ance in PAD.2 This suggests that antiplatelet treat-
ment with aspirin alone in PAD patients may be
sub-optimal.
Thienopyridine derivatives (e.g., clopidogrel) act by
a mechanism different to that of aspirin.2 They reduce
platelet activation by inhibiting the amplifying effect
of ADP.2 Their clinical effectiveness is supported by
trial-based evidence.2 Thus, clopidogrel was signifi-
cantly more effective than aspirin in preventing
major vascular events (myocardial infarction, stroke
and vascular death) in a large randomised double-
blind trial (CAPRIE; 19 185 patients).3 Heterogeneity
was seen among the three CAPRIE patient subgroups
(patients with myocardial infarction, stroke or PAD).3
The patients with PAD showed a significantly greater
benefit with clopidogrel than with aspirin resulting in
a relative-risk reduction of 23.8% (p 0.0028), com-
pared with 8.7% overall (p 0.043).2±4 However, this
trial was not designed for subgroup analysis. Never-
theless, this interpretation is in agreement with previ-
ous reports of enhanced platelet activation and
aspirin-resistance in PAD.2
Other trials demonstrated the effectiveness of the
clopidogrel aspirin combination after coronary
artery stenting5 and acute coronary syndrome.6 On
the negative side, combination therapy may increase
peri-operative bleeding in patients undergoing sur-
gery.7 We showed that a loading dose of clopidogrel
(300 mg) causes platelet inhibition within 2±4 h in
patients with PAD (unpublished results). We also
showed (unpublished results) that treatment with clo-
pidogrel (75 mg/day) inhibits platelet shape change
(PSC) in patients with PAD. PSC is an early phase of
platelet activation that is essentially aspirin resistant,
at least in vitro.8
A switch from aspirin, an effective, cheap and widely
prescribed drug in patients with PAD requires evi-
dence from comparative trials. However, in the light
of currently available evidence, this replacement may
be reasonable in PAD patients who have a vascular
event despite taking aspirin. Another alternative in
this situation is to add clopidogrel to aspirin. Clopido-
grel is also probably the drug of choice for PAD
patients who cannot tolerate aspirin, as stated by
Burns et al.1 Although these options are currently not
evidence based, they may be realistic choices for
patients with PAD.
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